002393 Tianjin Lisheng Pharmaceutical
- 16.50
- -0.10-0.60%
Tianjin Lisheng Pharmaceutical News
Lisheng Pharmaceutical Avails of 92-Day Structured Deposit Product
Lisheng Pharmaceutical (SHE:002393) availed of a 92-day, 150 million yuan structured deposit product from China Bohai Bank (HKG:9668), according to a Tuesday filing by parent company Tianjin Developme
Tianjin Dev (00882): Tianjin Lisheng Pharmaceutical subscribes to a total principal amount of 210 million yuan of structured deposits.
Tianjin DEV (00882) announced that on April 30, 2024, its indirectly non-wholly subsidiary Tianjin Lisheng Pharmaceutical and CBHB signed the first CBHB wealth management agreement to subscribe to structured deposits with a principal amount of RMB 60 million. On June 11, 2024, Lisheng Pharmaceutical and CBHB signed the second CBHB wealth management agreement to subscribe to structured deposits with a principal amount of RMB 150 million.
Lisheng Pharmaceutical (002393.SZ) 2023 equity distribution: transfer 4 shares to 6 yuan for every 10 shares
Lisheng Pharmaceutical (002393.SZ) issued an announcement. The 2023 equity distribution plan is: to all shareholders for every 1...
Express News | Lisheng Pharmaceuticals: Public listing and transfer of 24.65% of shares in Tianjin Tanabe Pharmaceutical Co., Ltd.
Tianjin Development (00882.HK): Lisheng Pharmaceuticals' net profit of 59,155,600 yuan in the first quarter increased 27.22% year-on-year
Gelonghui, April 25 | Tianjin Development (00882.HK) announced that in the first quarter of 2024, Lisheng Pharmaceutical (002393.SZ) achieved operating income of 365 million yuan, up 8.71% year on year; net profit attributable to shareholders of listed companies (Lisheng Pharmaceutical) was 59,1556 million yuan, up 27.22% year on year; net profit attributable to shareholders of listed companies (Lisheng Pharmaceuticals) after deducting non-recurring profit and loss was 58.7736 million yuan, up 29.71% year on year; basic earnings per share were 0.32 yuan.
Lisheng Pharmaceutical (002393.SZ): Net profit of 59.1556 million yuan in the first quarter increased 27.22% year-on-year
On April 24, Ge Longhui Pharmaceutical (002393.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 365 million yuan, up 8.71% year on year; net profit attributable to shareholders of listed companies was 59.1556 million yuan, up 27.22% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 58.7736 million yuan, up 29.71% year on year; basic earnings per share were 0.32 yuan.
Express News | Compound high-growth stocks released, only 21
Lisheng Pharmaceutical (002393.SZ): Number of shareholders as of April 10, 2024 was 18,744
Gelonghui, April 18, 丨 Lisheng Pharmaceutical (002393.SZ) said on the investor interactive platform that the number of shareholders of the company as of April 10, 2024 was 18,744.
Lisheng Pharmaceutical (002393.SZ): Has a production capacity of more than 10 billion tablets (tablets) per year for oral solid preparations
Gelonghui, April 18 | Lisheng Pharmaceutical (002393.SZ) said on the investor interactive platform that the company holds the drug number for potassium iodide tablets and has a production capacity of more than 10 billion tablets (tablets) per year for oral solid preparations. If the market needs it, the company can organize production at any time to ensure market supply. The indications for potassium iodide tablets produced by the company are: prevention and treatment of endemic goiter, thyroid function, preparation before surgery for hyperthyroidism, and hyperthyroidism crisis. For: prevention and treatment of endemic goiter, thyroid function, preparation before surgery for hyperthyroidism, and hyperthyroidism crisis.
Lisheng Pharmaceuticals (002393.SZ): Existing products and product indications under development do not cover the field of prevention and treatment of nuclear radiation
Gelonghui, April 9, 丨 Li Sheng Pharmaceutical (002393.SZ) said on the investor interactive platform that our main products include Subisan indapamide tablets, Sanyu Jingxing tablets, Siffonil Cefdinil dispersible tablets, friendly hemp seed softgels, biochemical nadroparin calcium injections, biohydrogenated sodium trisphate lyophilized powder, sodium bicarbonate tablets, sodium bicarbonate tablets, and a series of vitamin tablets. Up to now, the indications of the company's current products and products under development have not covered the field of prevention and treatment of nuclear radiation.
Lisheng Pharmaceuticals (002393.SZ): Hydrocortisone sodium for pharmaceutical injections passed generic drug consistency evaluation
Gelonghui, April 8, 丨 Li Sheng Pharmaceutical (002393.SZ) announced that recently, Tianjin Lisheng Pharmaceutical Co., Ltd. received the “Drug Supplement Application Approval Notice” (approval number: 2024B01369, 2024B01370) issued by the State Drug Administration for injectable hydrocortisone sodium (hereinafter referred to as the “drug”) of 50 mg (based on C21H30O5) and 0.1 g (based on C21H30O5). Indications for injectable hydrocortisone sodium succinate: used to rescue critically ill patients such as the following
Tianjin Development (00882): Central Pharmaceutical, a wholly-owned subsidiary of Lisheng Pharmaceuticals, received a civil ruling
Tianjin Development (00882) issued an announcement. Recently, Tianjin Lisheng Pharmaceutical Co., Ltd., a non-wholly-owned subsidiary of the company...
Lisheng Pharmaceutical (002393.SZ): The number of shareholders of the company as of March 27, 2024 was 17,850
Gelonghui March 27丨Lisheng Pharmaceutical (002393.SZ) said on the investor interactive platform that as of March 27, 2024, the number of shareholders of the company was 17,850.
Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains From Asset Disposals; Shares Jump 4%
Tianjin Lisheng Pharmaceutical's (SHE:002393) attributable profit surged to 361.8 million yuan, or 1.97 yuan per share, in 2023, from 93.6 million yuan, or 0.51 yuan per share, in 2022, according to a
Tianjin Development (00882.HK): Lisheng Pharmaceuticals' net profit increased by 286.54% to 362 million yuan in 2023
Gelonghui, March 22丨Tianjin Development (00882.HK) announced that in 2023, Lisheng Pharmaceutical (002393.SZ) achieved operating income of RMB 1.153 billion, up 0.56% year on year; net profit attributable to shareholders of listed companies was 362 million yuan, up 286.54% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 149.6 million yuan, up 20.26% year on year; basic earnings per share were 1.97 yuan.
Lisheng Pharmaceutical (002393.SZ): Net profit increased by 286.54% to 362 million yuan in 2023, plans to convert 10 to 4 to 6 yuan
Gelonghui, March 21丨Lisheng Pharmaceutical (002393.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 1.153 billion yuan, up 0.56% year on year; net profit attributable to shareholders of listed companies was 362 million yuan, up 286.54% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 149.6 million yuan, up 20.26% year on year; basic income per share was 1.97 yuan; it plans to distribute a cash dividend of 6.00 yuan (tax included) for every 10 shares to all shareholders, using capital reserves to all shareholders 10 shares were transferred to 4 shares.
Express News | Tianjin Development: The Group's comprehensive net profit attributable to company owners is expected to increase 70% to 80% year-on-year in 2023
Express News | Lisheng Pharmaceuticals: Tigrello's API approved for marketing application
Tianjin Development (00882): Lisheng Pharmaceutical's net profit for 2023 was 362 million yuan, an increase of 286.47% over the previous year
Tianjin Development (00882) announced Lisheng Pharmaceutical (002393.SZ) 2023, a non-wholly-owned subsidiary of the company...
Lisheng Pharmaceutical (002393.SZ) Performance Report: Net profit of 362 million yuan in 2023 increased 286.47% year-on-year
On February 26, Gelonghui Pharmaceutical (002393.SZ) announced its 2023 annual performance report. In 2023, the company achieved total operating revenue of 1.153 billion yuan, an increase of 0.56% over the same period last year. Achieved operating profit of 420 million yuan, an increase of 255.73% over the same period of the previous year; realized total profit of 420 million yuan, an increase of 255.17% over the same period of the previous year; realized net profit attributable to shareholders of listed companies of 362 million yuan, an increase of 286.47% over the same period of the previous year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss of 149.6 million yuan, a year-on-year increase
Analysis
Price Target
No Data
